[1] STANIFER J W, POKORNEY S D, CHERTOW G M, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease[J]. Circulation,2020,141(17):1384-1392. doi:  10.1161/CIRCULATIONAHA.119.044059
[2] YAO X X, TANGRI N, GERSH B J, et al. Renal outcomes in anticoagulated patients with atrial fibrillation[J]. J Am Coll Cardiol,2017,70(21):2621-2632. doi:  10.1016/j.jacc.2017.09.1087
[3] SIONTIS K C, ZHANG X S, ECKARD A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States[J]. Circulation,2018,138(15):1519-1529. doi:  10.1161/CIRCULATIONAHA.118.035418
[4] 张震, 孙燕. HPLC法测定阿哌沙班中的有关物质[J]. 天津药学, 2014, 26(6):9-11. doi:  10.3969/j.issn.1006-5687.2014.06.004
[5] 孙媛媛, 赵云丽, 段蒙蒙, 等. 高效液相色谱法测定阿哌沙班中的有关物质[J]. 沈阳药科大学学报, 2017, 34(1):37-42.
[6] 周建光, 周颖奇. 新型口服抗凝药的特点和临床研究[J]. 临床药物治疗杂志, 2013, 11(5):8-14. doi:  10.3969/j.issn.1672-3384.2013.05.003
[7] 赵伟, 许海燕. 房颤患者脑卒中的预防: 新型抗凝药依度沙班与达比加群、利伐沙班、阿哌沙班疗效与安全性的比较[J]. 中华医学杂志, 2014, 94(33):2601. doi:  10.3760/cma.j.issn.0376-2491.2014.33.012
[8] KIMACHI M, FURUKAWA T A, KIMACHI K, et al. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease[J]. Cochrane Database Syst Rev,2017,11:CD011373.
[9] SU X L, YAN B J, WANG L H, et al. Oral anticoagulant agents in patients with atrial fibrillation and CKD: a systematic review and pairwise network meta-analysis[J]. Am J Kidney Dis,2021,78(5):678-689.e1. doi:  10.1053/j.ajkd.2021.02.328
[10] 陆璐, 张洁, 阎昭. 阿哌沙班治疗肿瘤相关性血栓栓塞的获益与风险[J]. 天津医科大学学报, 2021, 27(3):322-325.
[11] 陈崴, 张望, 余学清. 中国肾脏病临床研究现状与展望[J]. 临床肾脏病杂志, 2013, 13(1):7-9.
[12] LABOVITZ A J, ROSE D Z, FRADLEY M G, et al. Early apixaban use following stroke in patients with atrial fibrillation: results of the AREST trial[J]. Stroke,2021,52(4):1164-1171. doi:  10.1161/STROKEAHA.120.030042
[13] HAREL Z, MCARTHUR E, JEYAKUMAR N, et al. The risk of acute kidney injury with oral anticoagulants in elderly adults with atrial fibrillation[J]. Clin J Am Soc Nephrol,2021,16(10):1470-1479. doi:  10.2215/CJN.05920421
[14] GUREVITZ C, GILADI E, BARSHESHET A, et al. Comparison of low and full dose apixaban versus warfarin in patients with atrial fibrillation and renal dysfunction (from a national registry)[J]. Am J Cardiol,2021,159:87-93. doi:  10.1016/j.amjcard.2021.08.022
[15] 张晓雷, 周明眉, 贾伟, 等. 在体肠灌流模型及其在中药研究中的应用[J]. 上海中医药大学学报, 2010, 24(3):87-92.
[16] 莫李立, 王素军. 口服药物吸收模型的研究进展[J]. 广东药学院学报, 2011, 27(1):104-107. doi:  10.3969/j.issn.1006-8783.2011.01.026
[17] 张燕, 朱华旭, 郭立玮. 在体单向肠灌流模型研究小檗碱及其在复方配伍环境中的大鼠肠吸收特性[J]. 药学学报, 2012, 47(2):233-238. doi:  10.16438/j.0513-4870.2012.02.005
[18] 沈凯, 王景田. 药物肠吸收实验研究方法进展[J]. 中国新药杂志, 2003, 12(12):988-991. doi:  10.3321/j.issn:1003-3734.2003.12.004
[19] 王辉, 褚倩倩, 哈婧, 等. 阿哌沙班的合成新工艺[J]. 中国新药杂志, 2015, 24(11):1290-1294.
[20] FAGERHOLM U, JOHANSSON M, LENNERNÄS H. Comparison between permeability coefficients in rat and human jejunum[J]. Pharm Res,1996,13(9):1336-1342. doi:  10.1023/A:1016065715308
[21] OTSUKA Y, CHOULES M P, BONATE P L, et al. Physiologically-based pharmacokinetic modeling for the prediction of a drug-drug interaction of combined effects on P-glycoprotein and cytochrome P450 3A[J]. CPT Pharmacometrics Syst Pharmacol,2020,9(11):659-669. doi:  10.1002/psp4.12562